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Abstract
Introduction Undifferentiated arthritis (UA) has a variable
disease course; 40 to 50% of UA patients remit spontaneously,
while 30% develop rheumatoid arthritis (RA). Identifying the UA
patients who will develop RA is essential to initiate early
disease-modifying anti-rheumatic drug (DMARD) therapy.
Although the presence of bone erosions at baseline is predictive
for a severe destructive disease course in RA, the prognostic
importance of erosive joints for disease outcome in UA is
unknown. This study evaluates the predictive value of erosive
joints for the disease outcome in UA as measured by RA
development and disease persistency.
Methods Baseline hands and feet radiographs of 518 UA
patients were evaluated for erosions using a clinical definition as
well as the Sharp/van der Heijde method. After 1 year follow-up,
patients were re-assessed for the fulfilment of the 1987 ACR
classification criteria for RA. Disease persistency was defined as
the absence of sustained remission during all available follow-up
(mean 8 ± 3 years).
Results At baseline, 28.6% of UA patients had erosive joints.
Presence of ≥2 erosive joints showed a positive predictive value
for RA development of 53% and for persistent disease of 68%.
Patients with erosions that did not develop RA were less often
anticyclic citrullinated peptide antibody (ACPA)+ve, rheumatoid
factor (RF)+ve and had lower C-reactive protein (CRP),
erythrocytic sedimentation rate (ESR) and number of swollen
joints compared to those who developed RA. Feet erosions are
equally predictive compared to erosions at hands.
Conclusions Presence of ≥2 erosive joints at baseline in UA
patients gives a risk for RA development of 53% and for
persistent disease of 68%, indicating that erosions in UA are not
always predictive for unfavorable disease outcomes.
Introduction
Early undifferentiated arthritis (UA) is defined as any arthritis of
recent onset that cannot be classified according to the exist-
ing criteria for specific rheumatic disorders [1]. Patients with
early UA form a heterogeneous group exhibiting a variable dis-
ease course. Of patients with early UA, 40 to 50% remit spon-
taneously, whereas 30% develop rheumatoid arthritis (RA) [2-
4]. Recent data indicate that initiation of disease-modifying
anti-rheumatic drug (DMARD) therapy in an early stage is ben-
eficial and thus underlines the necessity to recognize those UA
patients that will develop RA [5].
In the clinical setting generally much impact is given to clinical
predictors of the disease outcome. In RA the early occurrence
of erosions is one of the most significant predictors for a
severe destructive disease course. In contrast, the prognostic
value of baseline erosions for the disease outcome in UA is
unknown. Even more, the definition of erosive disease is
unclear and different studies use different descriptions and
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EAC: Leiden Early Arthritis Cohort; ICC: intra-class correlation coefficient; Ig: immunoglobulin; IP: inter-phalangeal joint; LR: likelihood ratio; MCP: 
metacarpo-phalangeal joint; MRI: magnetic resonance imaging; MTP: metatarso-phalangeal joint; NPV: negative predictive value; PIP: proximal inter-
phalangeal joint; PPV: positive predictive value; RA: rheumatoid arthritis; RF: rheumatoid factor; ROC: receiver operating characteristic; SDC: small-
est detectable change; SENS: Simplified Erosion Narrowing Score; SHS: Sharp/van der Heijde scoring; UA: undifferentiated arthritis.Arthritis Research & Therapy    Vol 11 No 5    Thabet et al.
Page 2 of 9
(page number not for citation purposes)
cut-off values. Interestingly, the presence of erosions is part of
the 1987 American College of Rheumatology (ACR) classifi-
cation criteria for RA, but it is not specified how many erosions
are required and it only includes erosions in the hands and not
in the feet [6].
Considering the lack of knowledge on the prognostic value of
erosions in UA, the present study aims to: study the predictive
value of erosive joints in hands and feet for development of RA
in UA-patients; define the optimal number of erosive joints to
predict RA; define whether the predictive ability is different
between erosive joints in hands and feet; determine whether
information on erosive joints increases the discriminative abil-
ity of a recently developed prediction rule for RA-development
[7,8]; and investigate whether the results are different when
disease persistency is studied instead of the development of
RA according to the 1987 ACR criteria.
The presence of erosions was assessed using two methods.
First, as the present study aims to have results that are useful
for clinical practice, we defined an erosive joint as a joint with
at least one erosion, defined as a lesion with an interrupted
cortex. The number of erosive joints was counted. As such,
this definition is the same as the erosion score in the Simplified
Erosion Narrowing Score (SENS) and is in line with common
clinical practice [9]. Several other scoring methods quantify
the radiological joint destruction in more detail [10]. Com-
monly used are the Sharp and the Larsen methods with their
modifications [11,12]. Although these methods are very valu-
able for research purposes, they are difficult to use in clinical
practice [10] because they require specialized training and are
time-consuming [13,14]. We primarily studied the predictive
value of the number of erosive joints but also performed the
analyses using the erosion score of the Sharp/van der Heijde
scoring (SHS) method in which the size and number of ero-
sions per joint are weighted [15].
Materials and methods
Patients
The present study includes 518 early arthritis patients who
were included between 1993 and 2005 in the Leiden Early
Arthritis Cohort (EAC). This EAC is a prospective cohort
started in 1993 [16]. Patients were referred by general practi-
tioners when arthritis was suspected and inclusion took place
when arthritis was confirmed at physical examination and
symptom duration was less than two years. Written informed
consent was obtained from all participants. The study was
approved by the local Medical Ethical Committee. At inclusion,
patients were asked about their joint symptoms, disease dura-
tion and subjected to a physical examination. Blood samples
were taken for routine diagnostic laboratory screening (includ-
ing immunoglobulin (Ig)M-rheumatoid factor (RF)) and stored
to determine other autoantibodies at a later time. Follow-up
visits were performed on a yearly basis and included radio-
graphs of hands and feet. Patients who at baseline did not fulfil
the criteria for known rheumatic disorders and thus were
referred to as having UA (518 patients).
Radiographs
Baseline radiographs of the hands (anterioposterior view) and
feet (posterioanterior view) were available for all the 518 UA
patients and were evaluated by the same person (MT). Ero-
sions were defined according to the erosive score of the
SENS method that was developed for use in clinical practice,
by the presence of a joint with at least one erosion. Subse-
quently, the number of erosive joints was counted in the follow-
ing joints: in hands, the proximal inter-phalangeal (PIP) joint in
digits 1 to 5, the metacarpo-phalangeal (MCP) joint in digits 1
to 5 and 6 radio-carpal sites (base of metacarpal bone digit 1,
trapezium, lunate, scaphoid, distal ulna and distal radius) and
in feet, the inter-phalangeal (IP) joint digit 1 and metatarso-
phalangeal (MTP) joint in digits 1 to 5.
In addition, the radiographs were scored according to the
SHS method [15] assessing the same hand and feet joints as
the SENS method. In the present study, only the erosion
scores were studied while the joint space narrowing scores
were omitted. Of the radiographs, 10% were scored twice to
determine the intra-class correlation coefficient (ICC). With
10% rescoring, the erosive joint count according to the SENS
definition showed an ICC of 0.91 and a smallest detectable
change (SDC) of 0.92, while the erosion SHS scores showed
an ICC of 0.94 and an SDC of 1.04.
Disease outcome
All patients were followed prospectively. After one year of fol-
low up, the fulfilment of the 1987 ACR criteria for RA was eval-
uated. The second disease outcome was disease persistency.
As a generally accepted definition for persistency is lacking,
we defined disease persistency as the absence of sustained
remission during all available follow up (mean 8 ± 3 years).
Sustained remission was diagnosed when patients had no
swollen joints for at least one year, after cessation of eventual
DMARD therapy. The absence of swollen joints had to have
been observed by a rheumatologist for at least one year to
ensure that remission was not temporary, but rather sustained.
Most patients identified with remission were discharged from
the outpatient clinic. Although patients should have absence
of arthritis for at least one year according to the definition,
most patients with remission had a longer follow up after the
identification of remission (median of 16 months). Patients
who had a recurrence of their arthritis after discharge, could
easily return to the Leiden University Medical Center, the only
referral center for rheumatology in a health care region of
approximately 400,000 inhabitants. This occurred in six
patients and these patients were not classified as sustained
remission.Available online http://arthritis-research.com/content/11/5/R155
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Statistical analysis
Proportions were compared using the chi-squared test with
two degrees of freedom (Epi Info v6, CDC, Atlanta, Georgia,
USA). Differences in mean values between groups were ana-
lyzed with the Mann-Whitney U test. The positive predictive
values (PPV), negative predictive values (NPV), specificity,
sensitivity, and positive and negative likelihood ratios (LR)
were determined for several cut-off values of the erosive joint
count and erosion scores according to SHS method. Receiver
operating characteristic (ROC) curves for the different cut-off
values were constructed and the area under the curve (AUC)
provided a measure of the overall discriminative ability. SPSS
software, version 14.0 (Chicago, IL, USA), was used for data
analyses. P values less than 0.05 were considered statistically
significant.
Results
Predictive accuracy for RA development
From the 518 UA patients, 31% (n = 160) fulfilled the 1987
ACR classification criteria for RA after one year of follow-up.
Baseline characteristics of UA patients that did and did not
progress to RA are summarized in Table 1.
Overall, 148 of 518 (28.6%) UA patients had erosive joints at
baseline. Seventy-six of the 160 (42%) patients who devel-
oped RA had baseline erosive joints, compared with 81 of the
358 (22.6%) who did not develop RA (P ≤ 0.001).
Different cut-off values for erosive joint count were tested for
their PPV and NPV regardless the localization of erosive joints
(Table 2). The PPV of having one or more erosive joint was
45%. With higher cut-offs the PPV gradually increased. In the
presence of two or more, three of more and four or more ero-
sive joints the PPVs were roughly similar: 53 to 54%. For the
cut-off of having five or more erosive joints, the PPV was 73%.
As the 95% confidence interval (CI) were overlapping, it could
not be concluded that the PPV of one of these cut-off values
is statistically superior to the others. The specificity was signif-
icantly different between the cut-off of two or more erosive
joints (89%) compared with the cut-off of one or more erosive
joints (77%). Using higher cut-off values, the specificity grad-
ually increased but the 95% CI overlapped. Evaluating the
positive and negative LR revealed the cut-off of two or more
erosive joints had the best balance between the positive and
negative LRs.
Table 1
Baseline characteristics of the total population of UA patients and for the patients that did and did not develop RA within one year
Characteristic Total
(n = 518)
Developed RA
(n = 160)
Did not develop RA
(n = 358)
P LR+ LR-
Female gender n (%) 305 (59) 111 (69) 194 (54) 0.001 1.3 0.67
Age in years (Mean ± SD) 50.6 ± 16.5 56.3 ± 15 48 ± 16.5 < 0.001 - -
Symptom duration at inclusion in months (Mean ± SD) 4.9 ± 5.5 5.9 ± 6 4.4 ± 5.1 0.002 - -
Morning stiffness (Mean ± SD) 55.7 ± 89.9 82.9 ± 111.4 43.6 ± 75.6 < 0.001 - -
Tender joint count (Mean ± SD) 6.5 ± 6.3 9.5 ± 7.4 5.1 ± 5.3 < 0.001 - -
Swollen joint count (Mean ± SD) 3.8 ± 4 5.7 ± 5.1 2.9 ± 3.1 < 0.001 - -
HAQ score (Mean ± SD) 0.76 ± 0.6 0.9 ± 0.6 0.7 ± 0.6 < 0.001 - -
ESR (mm/hr) (Mean ± SD) 28.9 ± 24.4 36.8 ± 23.7 25.3 ± 23.9 < 0.001 - -
CRP (mg/L) (Mean ± SD) 20.6 ± 28.2 26.5 ± 29.1 17.9 ± 27.4 < 0.001 - -
RF positivity n (%) 125 (24.2) 76 (47.5) 49 (13.7) < 0.001 3.5 0.61
ACPA positivity n (%) 114 (23.4) 76 (50) 38 (11.3) < 0.001 4.4 0.56
**Having erosive joints in hands and/or feet n (%) 148 (28.6) 67 (41.9) 81 (22.6) < 0.001* 1.8 0.75
**Hands only n (%) 58 (11.2) 23 (14.4) 35 (9.8) 0.1 - -
**Feet only n (%) 46 (8.9) 22 (13.8) 24 (6.7) 0.009 - -
**Hands and feet n (%) 44 (8.5) 22 (13.8) 22 (6.2) 0.004 - -
SHS erosion score (mean ± SD) 0.8 ± 2 1.5 ± 3 0.5 ± 1.3 < 0.001 - -
ACPA = anticyclic citrullinated peptide antibody; CRP = C-reactive protein; ESR = erythrocytic sedimentation rate; HAQ = health assessment 
questionnaire; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; RA = rheumatoid arthritis; RF = rheumatoid factor; SD = standard 
deviation; SHS = Sharp/van der Heijde scoring; UA = undifferentiated arthritis.
Morning stiffness score on a 100 mm visual analogue scale.
* P value is calculated in reference to the no-erosion group; ** Defined as a broken cortex in at least 1 joint.Arthritis Research & Therapy    Vol 11 No 5    Thabet et al.
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Additionally, the predictive values of the SHS erosion score
were investigated in a similar way, using different cut-off values
(Table 3). In case of an erosion score of one ore more, 45% of
UA patients developed RA, which increased to 51 and 61% of
UA patients in the presence of an erosion score of two or more
and five or more, respectively. As such, the resulting PPVs and
NPVs were comparable with those obtained using the erosive
joint count. Also, here the cut off of an erosion score of two
had the best balance between the positive and negative LRs.
Assessing data on the total available duration of follow up,
implying that patients with differences in the duration of follow
up are compared, revealed that 23 UA patients (4.4%) devel-
oped RA later than one year after inclusion. Categorizing these
patients in the RA group and using the cut off of having at least
two erosive joints revealed a slightly higher PPV of 60% (95%
CI 50% to 71%) and a slightly lower NPV of 69% (95% CI
65% to 74%).
Effect of localization of erosion
Baseline erosions were present in the hands in 11.2% of UA
patients, in the feet in 8.9% of UA patients, and both in hands
and feet in 8.5% of UA patients (Table 1). From these data, it
cannot be concluded that the small joints in the feet are less
often erosive than the small joints in the hands because the
number of assessed joints in feet and hands are different, 12
versus 26, respectively. Moreover, the LR+ for erosive joints in
the feet is for all cut-off points somewhat higher as compared
with the LR+ for erosive joints in the hands with a similar LR-
(Tables 4 and 5). These data suggest that presence of ero-
sions in the joints of the feet is slightly more predictive than
erosions in the hand joints.
The frequency of erosions (with a cut off of two or more ero-
sive joints) in the MCP joints was 3.1% in those who devel-
oped RA compared with 2.2% in those who did not develop
RA (P = 0.6, PPV = 38.5%, LR+ = 1.4, LR- = 0.99). Erosive
PIP joints were present in 3.1% of the RA group compared
with 1.1% of the non-RA group (P = 0.1, PPV = 55.6%, LR+
= 2.8, LR- = 0.98). The frequency of erosions in the wrist joints
in the RA group was 4.4% compared with 1.1% in the non-RA
group (P = 0.04, PPV = 63.6%, LR+ = 3.9, LR- = 0.97).
Although the frequency of erosions in the MTP joints in the RA
group was 14.4% compared with 3.4% in the non-RA group
(P < 0.001, PPV = 67.6%, LR+ = 4.3, LR- = 0.88; Table 6).
Table 2
Predictive value for the progression from UA to RA within one year using different cut-off values for erosions in hands and/or feet
Number of erosive 
joints
n PPV (95% CI) NPV (95% CI) Specificity (95% CI) Sensitivity (95% CI) LR+ LR- AUC (SEM)
≥1 148 45 37-53 75 70-79 77 73-82 42 34-50 1.8 0.75 0.60 (0.028)
≥2 83 53 42-64 73 69-78 89 86-92 28 21-34 2.5 0.81 0.58 (0.028)
≥3 50 54 40-68 72 68-76 94 91-96 17 11-23 2.6 0.89 0.55 (0.028)
≥4 24 54 34-74 70 66-74 97 95-99 8 4-12 2.6 0.95 0.53 (0.028)
≥5 15 73 51-96 70 66-74 99 98-100 7 3-11 6.2 0.94 0.53 (0.028)
n = number of UA patients positive for this cut off.
AUC = area under the curve; CI = confidence interval; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; NPV = negative predictive 
value; PPV = positive predictive value; RA = rheumatoid arthritis; SEM = standard error of measurement; UA = undifferentiated arthritis.
Table 3
Predictive value for the progression from UA to RA within one year using the erosion score of the Sharp van der Heijde method with 
different cut-off values for erosions
SHS erosion score n PPV (95% CI) NPV (95% CI) Specificity (95% CI) Sensitivity (95% CI) LR+ LR- AUC (SEM)
≥1 148 45 37-53 75 70-79 77 73-82 42 34-50 1.9 0.75 0.60 (0.028)
≥2 92 51 41-61 73 69-78 87 84-91 29 22-36 2.3 0.80 0.58 (0.028)
≥3 61 52 40-65 72 68-76 92 89-95 20 14-26 2.5 0.87 0.56 (0.028)
≥4 39 56 41-72 71 67-75 95 93-98 14 8-19 2.9 0.90 0.55 (0.028)
≥5 23 61 41-81 71 67-75 97 96-99 9 4-13 3.5 0.94 0.53 (0.028)
n = number of UA patients positive for this cutoff.
AUC = area under the curve; CI = confidence interval; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; NPV = negative predictive 
value; PPV = positive predictive value; RA = rheumatoid arthritis; SEM = standard error of measurement; SHS = Sharp/van der Heijde scoring; 
UA = undifferentiated arthritis.Available online http://arthritis-research.com/content/11/5/R155
Page 5 of 9
(page number not for citation purposes)
Characteristics of erosive UA patients that did not 
develop RA
As we observed that 47% of the UA patients with at least two
erosive joints did not fulfill the 1987 ACR classification criteria
for RA after one year of follow up, we compared the baseline
characteristics of the patients who had at least two erosive
joints that did and did not progress to RA (Table 7). The ero-
sive patients that did not develop RA were less often anticyclic
citrullinated peptide antibody positive (P < 0.001), less often
RF positive (P = 0.01), had a lower erythrocytic sedimentation
rate (P = 0.004), a lower C-reactive protein (P = 0.005), a
lower tender joint count (P < 0.001), a lower swollen joint
count (P < 0.001) and experienced less severe morning stiff-
ness as recorded on a visual analogue scale (P = 0.04) com-
pared with the patients that progressed to RA.
Of the UA patients with baseline erosions who developed RA,
74% were treated with DMARDs in their first year (compared
with 34% of the erosive UA patients who did not develop RA)
and 66% of non-erosive UA patients who developed RA were
treated with DMARDs (compared with 21% of non-erosive UA
patients that did not develop RA). This indicates that rheuma-
tologists did not treat erosive patients more aggressively than
non-erosive patients. DMARDs used were methotrexate
(34.8%), hydroxychloroquine (29.3%), sulphasalazine (25%),
combination of methotrexate and hydroxychloroquine or sul-
phasalazine (8.7%), or other DMARDs (2.2%).
Contribution to the prediction rule for RA development
Recently, a prediction rule was published that estimates the
risk for individual UA patients to progress to RA using nine
commonly assessed clinical and serological variables [7].
Presence of erosions is not part of this rule. As we hypothe-
sized that using different cut offs or a different definition for
erosive joints (according to the SENS method) may affect the
predictive ability of the prediction rule, data on the number of
erosive joints were added to the logistic regression model with
a backward selection procedure that was used to derive the
prediction rule [7]. For all the different cut-off values used, the
presence of erosive joints was not an independent predictor
for RA development (data not shown), and thus this informa-
tion did not improve the predictive ability of the model.
When using the prediction rule, there is a group of patients
(25% of all UA patients) for whom no accurate prediction of
RA development can be made. These patients have a predic-
tion score between 6.0 and 8.0 and for these patients the PPV
for RA development is 48% and the NPV is 52%. It was tested
if the radiological data on erosions can serve as an extra pre-
dictive tool, improving the NPV and PPV for this specific group
Table 4
Predictive value for the progression from UA to RA within one year using different cut-off values for erosions in hands
Number of erosive 
joints
n PPV (95% CI) NPV (95% CI) Specificity (95% CI) Sensitivity (95% CI) LR+ LR- AUC (SEM)
≥1 103 44 34-53 72 68-77 84 80-88 28 21-35 1.7 0.86 0.56 (0.028)
≥2 38 55 40-71 71 67-75 95 93-98 13 8-18 2.8 0.91 0.54 (0.028)
≥3 18 56 33-79 70 66-74 98 96-99 6 3-10 2.8 0.96 0.52 (0.028)
≥4 9 67 36-98 70 66-74 99 98-100 4 1-7 4.5 0.97 0.52 (0.028)
≥5 7 71 38-100 70 66-74 99 99-100 3 0-6 5.6 0.97 0.51 (0.028)
n = number of UA patients positive for this cutoff.
AUC = area under the curve; CI = confidence interval; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; NPV = negative predictive 
value; PPV = positive predictive value; RA = rheumatoid arthritis; SEM = standard error of measurement; UA = undifferentiated arthritis.
Table 5
Predictive value for the progression from UA to RA within one year using different cut-off values for erosions in feet
Number of erosive 
joints
n PPV (95% CI) NPV (95% CI) Specificity (95% CI) Sensitivity (95% CI) LR+ LR- AUC (SEM)
≥1 89 49 39-60 73 69-77 87 84-91 28 21-34 2.2 0.83 0.57 (0.028)
≥2 42 60 48-74 72 68-76 95 93-98 16 10-21 3.3 0.89 0.55 (0.028)
≥3 18 67 45-88 70 66-74 98 97-100 8 3-12 4.5 0.94 0.53 (0.028)
≥4 9 67 36-98 70 66-74 99 98-100 4 1-7 4.5 0.97 0.52 (0.028)
≥5 5 80 45-115 70 66-74 100 99-100 3 0-5 8.9 0.98 0.51 (0.028)
n = number of UA patients positive for this cutoff.
AUC = area under the curve; CI = confidence interval; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; NPV = negative predictive 
value; PPV = positive predictive value; RA = rheumatoid arthritis; SEM = standard error of measurement; UA = undifferentiated arthritis.Arthritis Research & Therapy    Vol 11 No 5    Thabet et al.
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of UA patients (n = 139). When using the cut off of at least two
erosive joints, the PPV was 56% and the NPV was 63% [see
Additional data file 1]. Together these results indicate that
using data on joint erosion disease does not result in an impor-
tant further differentiation of the risk estimation for RA in
patients with UA additive to the predictive ability of the known
clinical and serological factors.
Predictive accuracy for disease persistency
As the outcome measure of fulfilling the 1987 ACR criteria for
RA might be subject to discussion (because these criteria
were not designed to identify RA in an early phase) and to cir-
cular reasoning (because the presence of hand erosions are
part of the ACR criteria), we also tested the ability of the pres-
ence of erosive joints to predict disease persistency, defined
as the absence of sustained remission. For this analysis we
used all available follow-up data, implying that the follow up
was not similar for all patients studied. During the whole period
of follow up, 39.6% (n = 205) of UA patients achieved clinical
remission, while the remaining 60.4% (n = 313) had a persist-
ent disease course (remained UA, developed RA or developed
a disease other than RA). The PPV for having a persistent dis-
ease course gradually increased with higher cut-off values
(Table 8). When using the cut-off value of having two or more
erosive joints, the PPV was 68% and the NPV was 41%.
These PPV are somewhat higher compared with the data on
RA development according to the ACR criteria, but because
of overlapping 95% CIs the differences were not significant. In
addition to the finding that from all UA patients with two or
more erosive joints 32.5% achieved sustained remission, it
was observed that from all UA patients that achieved sus-
tained remission, 13.2% already had at baseline at least two
Table 6
Predictive value for the progression from UA to RA within one year by location of erosive joints and cutoff of at least two erosive 
joints
Location of erosions n PPV (95% CI) NPV (95% CI) Specificity (95% CI) Sensitivity (95% CI) LR+ LR- AUC (SEM)
Wrist 7 63.6 32-88 69.8 66-74 98.9 97-100 4.4 2-9 3.9 0.97 0.52 (0.028)
MCP 5 38.5 15-68 69.3 65-73 97.8 95-99 3.1 1-8 1.4 0.99 0.50 (0.028)
PIP 5 55.6 23-85 69.5 65-73 98.9 97-100 3.1 1-8 2.8 0.98 0.51 (0.028)
MTP 23 67.6 5-9 71.6 67-76 96.6 94-98 14.4 10-21 4.3 0.88 0.56 (0.028)
n = number of UA patients positive for this cutoff.
AUC = area under the curve; CI = confidence interval; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; MCP = metacarpo-
phalangeal joint; MTP = metatarso-phalangeal joint; NPV = negative predictive value; PIP = proximal inter-phalangeal joint; PPV = positive 
predictive value; RA = rheumatoid arthritis; SEM = standard error of measurement; UA = undifferentiated arthritis.
Table 7
Baseline characteristics of the UA patients with erosions (≥2 erosive joints) that did and did not progress to RA within one year
Characteristic Total
(n = 83)
Developed RA
(n = 44)
Did not develop RA
(n = 39)
P
Female gender n (%) 44 (53) 26 (53.8) 18 (46.2) 0.2
Age in years (Mean ± SD) 61.5 ± 16 60.7 ± 16.4 62.5 ± 15.6 0.6
Symptom duration at inclusion in months (Mean ± SD) 6.5 ± 6.3 7.1 ± 7.4 5.7 ± 4.8 0.9
Morning stiffness (Mean ± SD) 74.9 ± 100.5 92.2 ± 114.4 55.4 ± 78.9 0.04
Tender joint count (Mean ± SD) 6.9 ± 5.8 9 ± 6.7 4.6 ± 3.7 <0.001
Swollen joint count (Mean ± SD) 4.7 ± 4 6 ± 4 3.2 ± 3.4 <0.001
HAQ score (Mean ± SD) 0.89 ± 0.74 0.9 ± 0.73 0.87 ± 0.75 0.9
ESR (mm/hr) (Mean ± SD) 34.7 ± 24.7 41.3 ± 24 27.2 ± 23.6 0.004
CRP (mg/L) (Mean ± SD) 27.8 ± 31.4 33.4 ± 30.4 21.5 ± 31.7 0.005
RF positivity n (%) 31 (37.3) 22 (50) 9 (23.1) 0.01
ACPA positivity n (%) 25 (32.5) 20 (51.3) 5 (13.2) < 0.001
SHS erosion score (mean ± SD) 4.2 ± 3.4 4.7 ± 4.3 3.7 ± 1.8 0.4
ACPA = anticyclic citrullinated peptide antibody; CRP = C-reactive protein; ESR = erythrocytic sedimentation rate; HAQ = health assessment 
questionnaire; RA = rheumatoid arthritis; SD = standard deviation; SHS = Sharp/van der Heijde scoring; UA = undifferentiated arthritis.
Morning stiffness score on a 100-mm visual analogue score.Available online http://arthritis-research.com/content/11/5/R155
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erosive joints. For all cut-off values for the number of erosive
joints the positive and negative LRs were around one (Table
8).
Discussion
The current study explored the prognostic value of the pres-
ence of erosive joints for RA-development (defined by fulfil-
ment of the 1987 ACR classification criteria) and for having a
persistent disease course in patients with recent-onset UA. As
the primary aim was to determine the risk on these disease
outcomes for individuals, so that the results are useful for clin-
ical practice, we concentrated on the PPV and NPV and put
less emphasis on the sensitivity and specificity, which provide
information on the quality of the test. The LRs compare proba-
bilities of true results to false results and as such also provide
information on the test but not on absolute probabilities for
individuals. The PPV and NPV are dependent on the preva-
lence of the disease in the population and therefore the results
of the present study apply to recent-onset UA patients seen by
rheumatologists.
We observed that in the presence of at least two erosive
joints, the PPV for RA-development within one year was 53%
and the PPV for persistent disease was 68%. The presence of
one or more erosive joint had a lower PPV (45%) and the pres-
ence of three or more or four or more erosive joints was not
more predictive compared with the presence of two or more
erosive joints (PPV 54% versus 53%). Thus, a considerable
proportion of UA patients with erosive joints do not progress
to RA. Additionally, the LRs for disease persistency were
around one, illustrating the low impact of the quantity of ero-
sions for the likelihood of persistent disease. Although in
patients with RA, the presence of baseline erosions is a potent
predictor for a severe destructive disease course, the present
data implicate that for personalized medicine in UA, informa-
tion on the presence of erosions alone is inadequate to obtain
optimal treatment decision making.
The present data revealed that the PPVs and NPVs for having
erosions in the feet joints were at least equal to the predictive
values for having erosions in the small joints of the hands, and
from all joints studied the LR+ was the highest for the MTP
joints. This is notable as in the 1987 ACR classification criteria
for RA [6], the presence of erosions in hands are included but
feet erosions are not. In line with a previous study [17], the cur-
rent study suggests that the presence of feet erosions should
form part of the classification criteria as well.
Recently, a prediction rule for RA development was developed
and validated [7,8,18], and presence of erosions was not part
of this rule. The data presented revealed that radiological data
on erosions, regardless of its definition, does not importantly
improve the predictive ability of the prediction rule that is
based on common clinical and serological risk factors.
In order to have a similar duration of follow up for all studied
UA patients, progression to RA was evaluated after one year.
This might have introduced misclassification because patients
may have fulfilled the ACR criteria later on in the disease.
Therefore RA development was also recorded in the total avail-
able follow up (mean 8 ± 3 years). Of UA patients, 4.4% devel-
oped RA later than one year after inclusion. Taking these
patients into consideration led to a slight increase of the PPV
and decrease of the NPV although 95% CIs overlapped.
In the current study we evaluated erosions in anteroposterior
x-rays of the hands and posteroanterior x-rays of the feet with-
out additional planes. This is in accordance with clinical prac-
tice in the Netherlands and many other countries. The use of
an extra plane could have increased the sensitivity to detect
erosions, but at the costs of extra irradiation and financial
costs.
Data about the value of erosions detected by other new imag-
ing modalities such as sonography or magnetic resonance
Table 8
Predictive value for having persistent disease in UA patients using different cut-off values for number of erosive joints
Number of erosive 
joints
n PPV (95% CI) NPV (95% CI) Specificity (95% CI) Sensitivity (95% CI) LR+ LR- AUC (SEM)
≥1 148 65 57-73 41 36-46 75 69-81 31 26-36 1.2 0.93 53 (0.026)
≥2 83 68 57-78 41 36-46 87 82-92 18 14-22 1.4 0.95 52 (0.026)
≥3 50 70 57-83 41 36-45 93 89-96 11 8-15 1.5 0.96 52 (0.026)
≥4 24 68 48-86 40 36-44 96 93-99 5 3-8 1.3 0.99 51 (0.026)
≥5 15 73 51-96 40 36-44 98 96-100 4 2-6 1.8 0.98 51 (0.026)
n = number of UA patients positive for this cutoff.
Patients with remission 205 (39.6%).
Patients with persistent disease 313 (60.4%).
AUC = area under the curve; CI = confidence interval; LR+ = positive likelihood ratio; LR- = negative likelihood ratio; NPV = negative predictive 
value; PPV = positive predictive value; SEM = standard error of measurement; UA = undifferentiated arthritis.Arthritis Research & Therapy    Vol 11 No 5    Thabet et al.
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imaging (MRI) in UA population are scarce. Duer and col-
leagues investigated the value of MRI erosions in UA patients
without erosions at conventional radiography and found that
the presence of MRI erosions has a PPV of 50%, a NPV of
85%, a LR+ of 2.7 and a LR- of 0.5 for prediction of RA devel-
opment [19]. Tamai and colleagues studied the predictive
value of MRI erosions (without knowledge if these were radio-
graphically visible) and observed a PPV of 81.5%, a NPV of
48%, a LR+ of 3.18 and a LR- of 0.78 [20].
Several studies have shown that the current ACR criteria are
not well suited for establishing early RA [21-24]. In the current
study, many UA patients had arthritis in few joints, were sero-
positive and had erosive joints. Because they did not fulfill the
1987 ACR criteria for RA at baseline they were classified as
UA but not as RA. This may also illustrate that the 1987 ACR
criteria are not sensitive to diagnose RA at an early stage and
further implies the need for new classification criteria suitable
for early RA. Moreover, determining the predictive values of
baseline erosions for the development of RA according to the
ACR criteria can lead to circular reasoning as hand erosions
are part of the criteria. Therefore, we studied the predictive
accuracy for having persistent disease as well. This is in line
with previous studies which used persistent disease as an out-
come measure in UA patients [24,25]. Although thorough
investigation of the medical files taught us that the group of
patients with persistent disease is heterogeneous and the
available duration of follow up in which persistency/remission
is assessed differed between patients, the predictive values
for RA development and disease persistency were in the same
range.
Conclusions
In conclusion, the presence of erosions in small joints of the
hands and feet in UA patients at first presentation gives a risk
for RA development of 53% after one year and a risk for per-
sistent disease of 68%. These data imply that in early UA
baseline erosions are not always predictive for a poor disease
outcome and are on their own insufficient to found treatment
decisions.
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